Pulmonary hypertension:
Indications for: TYVASO DPI
To improve exercise ability in patients with: pulmonary arterial hypertension (WHO Group 1) with NYHA Class III symptoms; and pulmonary hypertension associated with interstitial lung disease (WHO Group 3).
Adult Dosage:
Give 4 separate, equally spaced treatment sessions each day approximately 4hrs apart, during waking hours. ≥18yrs: Initially 16mcg per treatment session. Maintenance: increase by 16mcg per session at approximately 1–2 week intervals; target dose usually: 48–64mcg per session. Dosage for transition from Tyvaso Inhalation Solution: see full labeling.
Children Dosage:
<18yrs: not established.
TYVASO DPI Warnings/Precautions:
Risk of symptomatic hypotension in those with low systemic arterial pressure. Hepatic insufficiency; titrate slowly. Risk of bleeding. Asthma, COPD, or other bronchial hyperreactivity. For Tyvaso Inhalation Solution: avoid contact with eyes and skin, oral ingestion. Elderly. Pregnancy. Nursing mothers.
See Also:
TYVASO DPI Classification:
Prostacyclin analogue.
TYVASO DPI Interactions:
Do not use with other medications. May be potentiated by CYP2C8 inhibitor (eg, gemfibrozil). May be antagonized by CYP2C8 inducer (eg, rifampin).
Adverse Reactions:
Cough, headache, nausea, diarrhea, dizziness, flushing, throat irritation, pharyngolaryngeal pain, syncope, dyspnea; symptomatic hypotension, bleeding, bronchospasm.
Drug Elimination:
Renal (79%), fecal (13%). Half-life: ~4 hours (Tyvaso Inhalation Solution); 27–50 minutes (Tyvaso DPI).
Generic Drug Availability:
NO
How Supplied:
Ampules (2.9mL)—4; Starter Kit—1 (28 ampules with inhalation system); Refill Kit—1 (28 ampules with accessories); DPI Titration Kit—1 (112 cartridges [16mcg] + 84 cartridges [32mcg] w. 5 inhalers); (112 cartridges [16mcg] + 112 cartridges [32mcg] + 28 cartridges [48mcg] w. 5 inhalers); DPI Maintenance Kit—1 (112 cartridges [16mcg, 32mcg, 48mcg, or 64mcg] w. 5 inhalers); (112 cartridges [32mcg] + 112 cartridges [48mcg] w. 5 inhalers)
